---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-24-000031"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:54:18.043266+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent

## Summary
- Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023
- Cash and cash equivalents $226.9M as of June 30, 2024, down from $255.4M at May 30 separation
- Separation from Inhibrx, Inc. completed May 30: INBRX-101 transferred to Sanofi for ~$2.2B
- Stockholders received $30 cash per share, one $5 CVR, and one Inhibrx Biosciences share per four former parent shares

## SEC filing metadata
- accession: 0002007919-24-000031
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/0002007919-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/inhibrx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-24-000031
- JSON: https://secwatch.observer/filing/0002007919-24-000031.json
- Plain text: https://secwatch.observer/filing/0002007919-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.